CEO Bruce Clark said, if the vaccine is successful, it could be available to the wider public by November 2021. “These timelines are heavily reliant on what will give the regulators enough comfort to say this product is ready to go into human testing and then, secondly, for use in the broader public,” he said. “Our best guess right now is 18 months.”
Within just 20 days of obtaining the gene of the virus, Medicago researchers were able to produce a candidate vaccine, Clark said. The biopahrmaceutical company used a plant-based platform to grow vaccine proteins rather than chicken embryos, allowing for them to make the vaccine candidate quickly.